Document Detail

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.
MedLine Citation:
PMID:  12361815     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Candida esophagitis remains an important cause of morbidity in patients with advanced human immunodeficiency virus (HIV) infection. Fluconazole is widely regarded as the treatment of choice for this condition. METHODS: The efficacy and safety of caspofungin were compared with fluconazole in adult patients with Candida esophagitis in a double-blind randomized trial. Eligible patients had symptoms compatible with esophagitis, endoscopic demonstration of mucosal plaques, and microscopic demonstration of Candida from the esophageal lesions. Patients were randomly assigned to receive caspofungin (50 mg) or fluconazole (200 mg) intravenously once daily for 7 to 21 days. The primary endpoint was the combined response of symptom resolution and significant endoscopic improvement 5 to 7 days after discontinuation of treatment. Data were analyzed with a modified intention-to-treat analysis, which excluded 2 ineligible patients. RESULTS: Most patients (154/177; 87%) had HIV infection, with a median CD4 count of 30 cells/mm(3). Candida albicans was the predominant isolate. Favorable response rates were achieved in 66 (81%) of the 81 patients in the caspofungin arm and in 80 (85%) of the 94 patients in the fluconazole arm (difference = -4%; 95% confidence interval: -15% to +8%). Symptoms had resolved in >50% of patients in both groups by the fifth day of treatment. No patient in the caspofungin group developed a serious drug-related adverse event; therapy was only discontinued in 1 patient (receiving fluconazole) due to a drug-related adverse experience. Four weeks after stopping study drug, symptoms had recurred in 18 (28%) of 64 patients given caspofungin and in 12 (17%) of 72 patients given fluconazole (P = 0.19). CONCLUSIONS: In this study, caspofungin appeared to be as efficacious and generally as well tolerated as fluconazole in patients with advanced HIV infection and documented Candida esophagitis.
Alvaro Villanueva; Eduardo Gotuzzo; Eduardo G Arathoon; L Miguel Noriega; Nicholas A Kartsonis; Robert J Lupinacci; Juanita M Smietana; Mark J DiNubile; Carole A Sable
Related Documents :
3805655 - Adenocarcinoma of the lower esophagus. a disease primarily of white men with barrett's ...
7706965 - Botulinum a toxin treatment in spasmodic torticollis: report of 56 patients.
16004175 - Actinomycosis esophagitis in a patient with persistent dysphagia.
20948735 - Diagnosis and treatment of eosinophilic esophagitis.
1858765 - Alpha 1-antitrypsin clearance as an aid in the management of patients with celiac disease.
2137745 - Computed tomographic peritoneography in the investigation of abdominal wall and genital...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of medicine     Volume:  113     ISSN:  0002-9343     ISO Abbreviation:  Am. J. Med.     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2002-10-03     Completed Date:  2002-10-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  294-9     Citation Subset:  AIM; IM    
Preventio, Barranquilla, Colombia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
AIDS-Related Opportunistic Infections / drug therapy*,  pathology
Anti-Bacterial Agents / administration & dosage,  therapeutic use*
Antifungal Agents / administration & dosage,  therapeutic use*
Candidiasis, Oral / drug therapy*,  pathology
Double-Blind Method
Drug Administration Schedule
Esophagitis / drug therapy*,  pathology
Fluconazole / administration & dosage,  therapeutic use*
Infusions, Intravenous
Middle Aged
Peptides, Cyclic*
Treatment Outcome
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Antifungal Agents; 0/Echinocandins; 0/Peptides; 0/Peptides, Cyclic; 0/caspofungin; 86386-73-4/Fluconazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of end-of-month admission on length of stay and quality of care among inpatients with myocar...
Next Document:  Cost-effectiveness of newer treatment strategies for influenza.